Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban-containing dual antiplatelet strategies in elderly patients with atrial fibrillation and acute coronary syndrome without revascularization
ChiCTR1800014852Phase 4Recruiting
- Sponsor
- Tianjin Union Medical Center
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban, aspirin and clopidogrel in acute coronary syndrome (ACS) and Atrial fibrillation (AFib) (3 arms), sponsored by Tianjin Union Medical Center. Primary endpoints: Left ventricular ejection fraction at 12 months, Estimated pulmonary artery pressure at 12 months and 7 more. Started Jun 2018; status: recruiting.
02
Drugs
rivaroxabanaspirinclopidogrel
03
Conditions
acute coronary syndrome (ACS)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR1800014852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014852.